Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: A retrospective series

Catherine Harrison-Balestra, William H. Eaglstein, Anna F. Falabela, Robert Kirsner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND. Recombinant human platelet-derived growth factor-BB (rhPDGF-BB or rhPDGF gel 0.01%) has been approved by the U.S. Food and Drug Administration (FDA) for topical use on lower extremity, neuropathic, diabetic ulcers to enhance healing and has been reported to be effective in expediting the healing of full-thickness chronic pressure ulcers. Published clinical data using rhPDGF gel to treat nondiabetic and nonpressure-related ulcers have been limited. OBJECTIVE. To determine the effectiveness of topical rhPDGF gel in treating refractory chronic ulcers other than diabetic, neuropathic ulcers. METHODS. A retrospective chart review was performed on patients without diabetes mellitus-related ulcers treated with topical rhPDGF gel 0.01%. RESULTS. Twelve patients with 14 ulcers were treated. Nine of 14 ulcers healed (64%) with a mean time to healing of 26 weeks. Two of the nine healed ulcers (22%) reopened during a 15-month follow-up period. CONCLUSION. rhPDGF gel is an effective and well-tolerated treatment for refractory chronic ulcers.

Original languageEnglish
Pages (from-to)755-760
Number of pages6
JournalDermatologic Surgery
Volume28
Issue number8
DOIs
StatePublished - Aug 1 2002

Fingerprint

Platelet-Derived Growth Factor
Ulcer
Gels
Pressure Ulcer
United States Food and Drug Administration
Lower Extremity
Diabetes Mellitus

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers : A retrospective series. / Harrison-Balestra, Catherine; Eaglstein, William H.; Falabela, Anna F.; Kirsner, Robert.

In: Dermatologic Surgery, Vol. 28, No. 8, 01.08.2002, p. 755-760.

Research output: Contribution to journalArticle

Harrison-Balestra, Catherine ; Eaglstein, William H. ; Falabela, Anna F. ; Kirsner, Robert. / Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers : A retrospective series. In: Dermatologic Surgery. 2002 ; Vol. 28, No. 8. pp. 755-760.
@article{b4b7c2d0439542de976303b004464b35,
title = "Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: A retrospective series",
abstract = "BACKGROUND. Recombinant human platelet-derived growth factor-BB (rhPDGF-BB or rhPDGF gel 0.01{\%}) has been approved by the U.S. Food and Drug Administration (FDA) for topical use on lower extremity, neuropathic, diabetic ulcers to enhance healing and has been reported to be effective in expediting the healing of full-thickness chronic pressure ulcers. Published clinical data using rhPDGF gel to treat nondiabetic and nonpressure-related ulcers have been limited. OBJECTIVE. To determine the effectiveness of topical rhPDGF gel in treating refractory chronic ulcers other than diabetic, neuropathic ulcers. METHODS. A retrospective chart review was performed on patients without diabetes mellitus-related ulcers treated with topical rhPDGF gel 0.01{\%}. RESULTS. Twelve patients with 14 ulcers were treated. Nine of 14 ulcers healed (64{\%}) with a mean time to healing of 26 weeks. Two of the nine healed ulcers (22{\%}) reopened during a 15-month follow-up period. CONCLUSION. rhPDGF gel is an effective and well-tolerated treatment for refractory chronic ulcers.",
author = "Catherine Harrison-Balestra and Eaglstein, {William H.} and Falabela, {Anna F.} and Robert Kirsner",
year = "2002",
month = "8",
day = "1",
doi = "10.1046/j.1524-4725.2002.02004.x",
language = "English",
volume = "28",
pages = "755--760",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers

T2 - A retrospective series

AU - Harrison-Balestra, Catherine

AU - Eaglstein, William H.

AU - Falabela, Anna F.

AU - Kirsner, Robert

PY - 2002/8/1

Y1 - 2002/8/1

N2 - BACKGROUND. Recombinant human platelet-derived growth factor-BB (rhPDGF-BB or rhPDGF gel 0.01%) has been approved by the U.S. Food and Drug Administration (FDA) for topical use on lower extremity, neuropathic, diabetic ulcers to enhance healing and has been reported to be effective in expediting the healing of full-thickness chronic pressure ulcers. Published clinical data using rhPDGF gel to treat nondiabetic and nonpressure-related ulcers have been limited. OBJECTIVE. To determine the effectiveness of topical rhPDGF gel in treating refractory chronic ulcers other than diabetic, neuropathic ulcers. METHODS. A retrospective chart review was performed on patients without diabetes mellitus-related ulcers treated with topical rhPDGF gel 0.01%. RESULTS. Twelve patients with 14 ulcers were treated. Nine of 14 ulcers healed (64%) with a mean time to healing of 26 weeks. Two of the nine healed ulcers (22%) reopened during a 15-month follow-up period. CONCLUSION. rhPDGF gel is an effective and well-tolerated treatment for refractory chronic ulcers.

AB - BACKGROUND. Recombinant human platelet-derived growth factor-BB (rhPDGF-BB or rhPDGF gel 0.01%) has been approved by the U.S. Food and Drug Administration (FDA) for topical use on lower extremity, neuropathic, diabetic ulcers to enhance healing and has been reported to be effective in expediting the healing of full-thickness chronic pressure ulcers. Published clinical data using rhPDGF gel to treat nondiabetic and nonpressure-related ulcers have been limited. OBJECTIVE. To determine the effectiveness of topical rhPDGF gel in treating refractory chronic ulcers other than diabetic, neuropathic ulcers. METHODS. A retrospective chart review was performed on patients without diabetes mellitus-related ulcers treated with topical rhPDGF gel 0.01%. RESULTS. Twelve patients with 14 ulcers were treated. Nine of 14 ulcers healed (64%) with a mean time to healing of 26 weeks. Two of the nine healed ulcers (22%) reopened during a 15-month follow-up period. CONCLUSION. rhPDGF gel is an effective and well-tolerated treatment for refractory chronic ulcers.

UR - http://www.scopus.com/inward/record.url?scp=0036678903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036678903&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4725.2002.02004.x

DO - 10.1046/j.1524-4725.2002.02004.x

M3 - Article

C2 - 12174074

AN - SCOPUS:0036678903

VL - 28

SP - 755

EP - 760

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 8

ER -